Executive Summary
- Mission Bio and IDT partner to offer an integrated workflow combining single-cell DNA sequencing and amplicon-based targeted resequencing for genome editing validation.
- The integrated workflow aims to provide a more accurate and comprehensive assessment of genome editing outcomes, including on-target efficacy and off-target detection, at the single-cell level.
- The partnership anticipates demonstrating the workflow's capabilities at the upcoming ASGCT Annual Meeting, showcasing a robust and customizable solution for cell and gene therapy applications.
Event Overview
Mission Bio and Integrated DNA Technologies (IDT) have announced a partnership to advance precision in CRISPR genome editing analysis. By integrating IDT’s rhAmpSeq technology with Mission Bio’s Tapestri Platform, the collaboration aims to provide a comprehensive approach for assessing genome editing outcomes at the single-cell level. This workflow enhances the efficiency for obtaining both on-target efficacy assessment and off-target detection in a single-cell context, offering researchers an unprecedented level of accuracy and confidence in genome editing analysis.
Media Coverage Comparison
| Source | Key Angle / Focus | Unique Details Mentioned | Tone |
|---|---|---|---|
| Mission Bio Press Release | Partnership between Mission Bio and IDT to enhance CRISPR genome editing analysis | Mentions an upcoming presentation at the ASGCT Annual Meeting, the Tapestri Platform's automated single-cell genome editing analytics pipeline, and a proof-of-concept study using well-characterized cell lines. | Positive and promotional, highlighting the benefits of the partnership and technology. |
Key Details & Data Points
- What: Mission Bio and IDT are partnering to provide an integrated workflow combining IDT’s rhAmpSeq technology with Mission Bio’s Tapestri® Platform for precise on- and off-target confirmation in gene editing applications at the single-cell level.
- Who: Mission Bio, Integrated DNA Technologies (IDT), Brian Kim (CEO of Mission Bio), Sandy Ottensmann (VP/GM, Gene Writing and Editing at IDT), Dr. Ayal Hendel of Bar-Ilan University.
- When: Partnership announced May 6, 2025. Presentations at ASGCT Annual Meeting: poster on May 15 at 5:30 pm CST, oral presentation on May 17 at 9:00 am CST.
- Where: South San Francisco, CA (Mission Bio headquarters). ASGCT Annual Meeting location not specified.
Key Statistics:
- Key statistic 1: >2,000 bp (size of large insertions and deletions targeted in the proof-of-concept study)
- Key statistic 2: Single-cell resolution (level of detail provided by Mission Bio’s Tapestri Platform)
- Key statistic 3: N/A
Analysis & Context
The partnership between Mission Bio and IDT addresses a critical need in the field of cell and gene therapy: ensuring the specificity and efficiency of genome edits. Traditional bulk sequencing methods lack the resolution to capture single-cell heterogeneity, zygosity, and co-occurrence of edits within individual cells. By integrating IDT's rhAmpSeq technology with Mission Bio’s Tapestri Platform, the new workflow offers a more comprehensive and accurate assessment of genome editing outcomes. This advancement has the potential to accelerate the development of safer and more effective cell and gene therapies.
Notable Quotes
By integrating our capabilities with IDT’s trusted approach to bulk sequencing, we’re adding together multiple layers of genetic insights in a single drop.
By pairing the precision of rhAmpSeq with the single-cell resolution of Tapestri, we aim to support cell and gene therapy developers in driving the future of safe, life-changing therapies to benefit more patients.
Conclusion
The collaboration between Mission Bio and IDT marks a significant step forward in genome editing analysis. By combining their respective technologies, they provide a solution for more precise and comprehensive assessment of genome editing outcomes. The integrated workflow has the potential to accelerate the development of safer and more effective cell and gene therapies, benefiting patients in the long run. The upcoming presentations at the ASGCT Annual Meeting will further demonstrate the capabilities of this new approach.
Disclaimer: This article was generated by an AI system that synthesizes information from multiple news sources. While efforts are made to ensure accuracy and objectivity, reporting nuances, potential biases, or errors from original sources may be reflected. The information presented here is for informational purposes and should be verified with primary sources, especially for critical decisions.
